title: Dabigatran (Pradaxa).
abstract: Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). It may supplant warfarin (Coumadin) in a number of applications as it may produce a more predictable, potent, and immediate anticoagulant effect, with fewer significant side effects and interactions, and requires less monitoring.
authors.affiliation: St Vincent's Hospital, Melbourne, Australia. julescomin@gmail.com
authors.forename: J
authors.initials: J
authors.lastname: Comin
authors.forename: D F
authors.initials: DF
authors.lastname: Kallmes
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects* / Q000737:chemistry; D000069604:Dabigatran; D004305:Dose-Response Relationship, Drug; D006470:Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D013927:Thrombosis / Q000188:drug therapy*; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D015091:beta-Alanine; D000069604:Dabigatran